Purpose. Cervical cancer is the most frequently diagnosed female cancer in The Gambia, representing approximately 30 % of cases. In 2014, the quadrivalent human papilloma virus (HPV) vaccine was introduced, which offers protection against HPV genotypes 6, 11, 16 and 18. To evaluate the potential effectiveness of this vaccine, genotype distribution and risk factor analysis were assessed.
INTRODUCTION
Human papilloma virus (HPV) infection is the most common sexually transmitted infection in reproductive-age females, and is associated with approximately 80 % of cases of cervical cancer [1, 2] . More than 75 % of sexually active females will be infected with the virus at some stage in their lives, which in some cases can regress without treatment [3, 4] . However, persistent infection with HPV high-risk genotypes over a period of time can lead to cervical intraepithelial neoplasia (CIN), which can progress to cervical cancer [5] [6] [7] . Annually, more than 500 000 new cervical cancer cases and 250 000 deaths are reported worldwide [8] . Although cervical cancer is a global health problem, more than 80 % of these cases occur in Africa where regular cervical cancer screening programmes are not readily available. Cervical cancer survival rates are very low in developing countries due to either late presentation of cases or a lack of adequate treatment services [8, 9] .
Approximately 100 HPV genotypes have been identified, and 40 of these can infect the genital mucosal tract. According to the International Agency for Research on Cancer (IARC), 12 of these HPV mucosal types (HPV- 16, 18, 31, 33, 35, 39, 45 , 51, 52, 56, 58 and 59) are termed high-risk (HR-HPV) or oncogenic types [10] . HPV types 26, 53, 66, 67, 68, 70, 73 and 82 are classified as possible or probable high-risk (pHR-HPV) [11] . Low-risk (LR-HPV) types are associated mostly with condyloma acuminata, genital warts or other benign epithelial lesions. The most common LR-HPV genotypes are HPV-6 and HPV-11 [10, 12] . Although persistent infection with HR-HPV 16 and 18 is responsible for more than 70 % of cervical cancer cases, other HR-HPV genotypes have been identified as causative agents for cervical cancer and other genital and oropharyngeal cancers [12, 13] . While HPV infection is the major risk factor for the development of cervical cancer, several other co-factors are known to increase this risk [14] . These include having multiple sexual partners, the use of hormone contraceptives and smoking. Furthermore, co-infection with other sexually transmitted pathogens may enhance HPV persistence through immunosuppression and tissue damage, which can increase the risk of development of cervical neoplasia and cancer [15] .
In an attempt to reduce the burden of HPV infection, three recombinant HPV prophylactic vaccines have been developed: a bivalent vaccine, manufactured by GlaxoSmithKline that targets HR-HPV 16 and 18; a quadrivalent vaccine, marketed by Merck and Co, against HR-HPV 16, 18 and LR-HPV 6 and 11; and, more recently, Gardasil 9, from Merck and Co, has been licensed, which targets 7 HR-HPV genotypes 16, 18, 31, 33, 45, 52 , 58 and LR-HPV 6 and 11.
Although HPV infection is vaccine-preventable, widespread introduction of the vaccine in resource-limited countries is still in its infancy. In The Gambia, cervical cancer is the most frequently diagnosed cancer, representing approximately 30 % (161/545) of all diagnosed cases during the period 1998-2006 [16] . Furthermore, according to The Gambia Health Management Information System, 237 females were diagnosed with cervical cancer in 2016 and 96 % of these cases were from the urban part of the country (Banjul, Kanifing Municipal Council (KMC) and West Coast Region (WCR)).
In 2014, The Gambia introduced the quadrivalent HPV vaccine in the WCR, targeting females from 9 to 13 years. However, the major circulating HR-HPV genotypes are currently unknown in this population; therefore there is a need to collect current data on HPV infection rates and circulating genotypes. The aim of the study was to evaluate the potential value of the quadrivalent vaccine in urban Gambia by investigating the major circulating HR-HPV genotypes in females residing in this area. In addition, the presence of known socio-demographic risk factors for HPV infection was also determined in this population, as well as HPV coinfection with selected sexually transmitted pathogens.
METHODS

Study site and population
This study focused on residents of Banjul, Kanifing Municipal Council and the West Coast Region where the majority of cervical cancer cases are reported. Females aged 20-49 years attending the Edward Francis Small Teaching Hospital (EFSTH) sexual health clinic for primary health care were enrolled in this study. Informed consent (Fig. S1 , available in the online version of this article) was obtained and a participant information sheet (Fig. S2 ) was provided for those who agreed to participate.
Socio-demographic and risk factors data collection
To determine the social and economic implications of HPV in urban Gambia, a questionnaire was administered to each participant to capture socio-demographic and potential risk factors associated with HPV infection (Fig. S3) .
Sample collection and routine microbiological investigations Two hundred and thirty-five (235) females were recruited between August 2015 and February 2016. Two endocervical and two high vaginal swabs were collected from each participant, one endocervical and high vaginal swab from each patient being used for routine microbiological investigations and the remaining swabs for PCR amplification. Samples for PCR were placed immediately into specimen transport media (M4RT, micro-test, Oxoid, Basingstoke, UK), and stored at À70 C until ready for use.
Routine microbiological detection of Streptococcus agalactiae, Candida albicans, Neisseria gonorrhoeae, bacterial vaginosis and Trichomonas vaginalis was performed in the Department of Medical Microbiology, EFSTH, using standard operating procedures. For the isolation of Streptococcus agalactiae, Neisseria gonorrhoeae and Candida albicans, high vaginal and endocervical swabs were cultured onto defibrinated sheep blood agar, chocolate agar and Sabouraud agar (Oxoid, Basingstoke, UK). The blood and chocolate agar plates were incubated overnight at 37 C in an aerobic and a 6 % carbon dioxide atmosphere, respectively. Sabouraud plates were incubated aerobically at 28 C for up to 48 h to isolate Candida albicans or Candida species. Colonies of interest were subcultured and incubated overnight to generate pure colonies. These were selected for Gram staining and biochemical identification. Streptococcus agalactiae was identified using the Streptex rapid latex agglutination test (Thermo Fisher Scientific, Loughborough, UK), Neisseria gonorrhoeae was identified using the API NH test (Biom erieux, Basingstoke, UK) and Candida albicans was identified by a positive germ tube test. Trichomonas vaginalis was detected by vaginal wet mount microscopy for the detection of motile trichomonads. Bacterial vaginosis was diagnosed using Amsel's clinical criteria, by the presence of any three of the following: 1) a homogeneous white vaginal discharge; 2) a vaginal pH of !4.6; 3) the release of a 'fishy' amine odour when 10 % potassium hydroxide was added to a vaginal fluid sample; and 4) the presence of more than 20 % clue cells as observed by microscopy [17] .
DNA extraction DNA was extracted from the clinical specimens using the QIAamp DNA mini extraction kit (Qiagen, Crawley, UK) following the manufacturer's instructions. For quality control of the extraction process, sterile water was used as a negative control. A 5 µl volume of DNA was used in subsequent PCR reactions. Endocervical swabs were used for HPV PCR, while both endocervical and high vaginal swabs were used for Ureaplasma parvum/urealyticum PCR.
Polymerase chain reaction
All PCR amplifications were performed in a 25 µl volume containing 5 µM of each primer, 1x Taq PCR master mix containing 2.5 units of Taq DNA polymerase, 0.2 mM deoxynucleotide trisphosphates and 1.5 mM MgCl 2 (Qiagen, Crawley, UK) and 5 µl of DNA template. Amplified products were resolved by electrophoresis using 2 % (w/v) agarose gels.
Histocompatibility leucocyte antigen PCR
To assess the quality of the DNA extracts from clinical specimens prior to HPV PCR testing, the presence (or absence) of human cellular DNA was determined using a PCR assay targeting the histocompatibility leucocyte antigen (HLA) gene. HLA-PCR was carried out using the forward primer 5¢GTGGTGTAAACTTGTACCA-3¢ and reverse primer 5¢-GTAGCAGCGGTAGAGTT-3¢, which amplified a 230 base-pair (bp) region. Thermal cycling was performed as described elsewhere [18] . A positive HLA-PCR test was determined by the observation of a visible PCR product of the expected size following gel electrophoresis and ethidium bromide staining.
HPV late gene L1 consensus PCR
HLA-PCR positive samples were subjected to PCR that amplifies a 450 bp region of the HPV late gene 1 (L1) using the PGMY09/11 consensus primers. The L1 consensus PGMY09/11 primer pool consists of five upstream and 13 downstream oligonucleotides [18, 19] . A W.H.O. International standard HPV16 DNA positive control (NIBSC, Hertfordshire, UK), negative control (molecular-grade water) and a DNA extraction negative control were included in each PCR run. Thermal cycling was carried out as described elsewhere [18] .
Ureaplasma parvum/urealyticum PCR Conserved primers for two species of Ureaplasma (U. urealyticum and U. parvum), UU-1402 Forward 5¢-TGCTGG TGGTACAGGTATGAA-3¢and UU-1779 Reverse 5¢-GAG-CATGTCCACCACCA-3' were used, which target a 378 bp region of the urease gene [20] . Positive (Genekam Biotechnology, Duisburg, Germany), negative (molecular grade water) and DNA extraction-negative controls were included in each PCR reaction. The thermal cycling consisted of an initial denaturation at 95 C for 3 min, followed by 35 cycles of denaturation at 95 C for 30 s, annealing at 58 C for 30 s, elongation at 72 C for 30 s and a final extension step at 72 C for 5 min.
HPV genotyping by DNA sequencing PCR amplicons were purified using a PCR purification kit (Sigma Aldrich, Haverhill, UK) and then sequenced using the Sanger chain termination method. Raw sequence data are provided in Table S1 . An NCBI BLAST (http://www.ncbi. nlm.nih.gov/BLAST/) search was performed for each sequenced product to allocate the HPV genotype [18] .
Statistical analysis
Data analysis on HPV prevalence and risk characteristics was carried out using Epi Info version 7 (CDC, Atlanta, USA). Descriptive statistics such as frequency distributions and percentages were used to describe HPV prevalence and other related characteristics of the study population. Bivariate and multivariate analyses were carried out on the strength of risk factor association with HPV infection using odds ratio (OR), adjusted odds ratio (AOR) and confidence interval of 95 % (CI), and a P value of 0.05 was used to determine statistical significance.
RESULTS
Of the 235 participants recruited, three (1.3 %) samples contained inadequate cellular DNA and so were excluded from further analysis.
Socio-demographic and HPV risk characteristics of participants A total of 232 females aged 20-49 years were included in the study, with a mean age of 31.8 years (±7.5 SD). Thirty per cent of the participants were involved in petty trading as a means of economic subsistence, whilst 26 % identified as housewives. Eighty per cent of participants were married and 48.3 % had at least 12 years of education. Three participants (1.3 %) reported as being sexually inexperienced, although they did not have an intact hymen, and six (2.6 %) reported as having their sexual debut at the age of <14 years as a result of early marriage. Sixty-seven per cent (67 %) of participants had their sexual debut at the age of !18 years and approximately 40 % reported having two or more lifetime sexual partners. Sixty per cent (60 %) of participants reported their partners having other sexual partners, and more than 80 % reported never using a condom during sexual intercourse. Seventy-eight per cent (78 %) reported using hormone contraceptives. Approximately 63 % of participants had undergone female genital mutilation (FGM). Table 1 shows the socio-demographic and risk factor characteristics of participants, expressed as absolute values and percentages.
Multivariate analysis of HPV Risk Factors
Female genital mutilation, low annual income, fewer than 12 years of education and partners having other sexual partners were risk factors for HPV infection but were not associated significantly with the infection (P>0.05). Hormone contraceptive use for >5 years was found to be a risk factor and was associated significantly with HPV infection (AOR 4.2, P=0.03) ( Table 2) . Participants who had their sexual debut at the age of !18 years were twice as likely to be infected with HPV (AOR 2.2, P=0.17). Being married was found to be a protective factor against HPV infection; however, stratification analysis (not shown) indicated that married females who had sex in the preceding 12 months without using condoms were at increased risk of HPV infection (AOR 2.1, P>0.05). Table 2 shows the risk factor characteristics associated with HPV infection in this study.
HPV prevalence and genotype distribution
Of the 232 participants with adequate cellular DNA, HPV DNA was detected in 28. The overall HPV prevalence was found to be 12.1 %, with nine different HR/pHR and seven different LR genotypes identified. Twelve (42.9 %) women were infected with a HR-HPV genotype, four (15.4 %) with pHR carcinogenic types and 12 (42.9 %) with LR types. The most prevalent HR-HPV type detected was HPV 52 (17.9 %), followed by HPV 51 and 58, each at 7.1 %, and the most prevalent pHR-HPV was HPV 66 (7.1 %). HPV 61 was the most common LR-HPV genotype, accounting for 14.3 % of all genotypes.
HPV genotypes were allocated according to the IARC genotype classification using raw sequence data (Table S1 ) [10] . HPV genotypes with homology differences less than 2 % to the closest known genotypes were identified as HPV variant types (99-100 %), and those between 2 and 10 % were identified as subtypes (90-98 %). All HR/pHR-HPV genotypes identified in this study showed 98-100 % identity to DNA sequences deposited in the GenBank database except one which was nominally allocated as a subtype of HPV genotype 35, although it showed only 82 % identity to a known HPV 35 type (Table 3 ). The putative HPV 35 sequence was submitted to GenBank (accession number MH844101). Furthermore, none of the HPV sequences identified were homologous to HPV sequences isolated in Africa.
HPV prevalence by age and ethnic group
The HPV age-specific prevalence curve of participants showed a peak in the 21-25 age group (32.1 %), followed by a steady decline in the ages between 26 and 40 years, and a sharp decline was seen in later years. However, HR-HPV prevalence was higher in the 26-30-year age group (41.7 %) and pHR-HPV types were higher in the 21-25-year age group (75 %) ( Table 4) . HPV infection was not detected in the 20-year age group. Ethnicity-associated differences were also noted: HR/pHR HPV prevalence was higher in the Fulas (31.3 %), followed by the Mandinkas (18.8 %), and a lower prevalence was seen in the Wollofs (12.5 %). However, LR-HPV genotypes were identified mostly in the Mandinka ethnic group, accounting for more than 40 % of the LR types. The prevalence of both HR and LR-HPV genotypes was lower in the Wollofs compared to the other two major ethnic groups. The study also revealed a higher overall HPV prevalence in the Fula ethnic group (32.1 %), and this group were found to be more than twice at risk of HPV infection than the other two major ethnic groups (AOR 2.1, 95 % CI 1.0, 4.9) ( Table 2 ).
HPV and co-infection with other sexually transmitted pathogens
Of the 28 females positive for HPV, 14 (50 %) were coinfected with Ureaplasma parvum/urealyticum, five (18 %) with Candida albicans, three (10.7 %) with Streptococcus agalactiae, one (3.6 %) with Trichomonas vaginalis and four (14.8 %) were diagnosed with bacterial vaginosis. Of those positive for Ureaplasma parvum/urealyticum, 11 (79 %) were infected in both the vagina and cervix, two (14 %) in the cervix only and one (7 %) in the vagina only. In addition, of the 14 HPV-positive females who were co-infected with Ureaplasma, seven (50 %) were additionally co-infected with either Candida albicans or Trichomonas vaginalis or were diagnosed with bacterial vaginosis.
DISCUSSION
The introduction of any HPV vaccine prevention strategy requires consideration of the major circulating HR-HPV genotypes in the population. HPV genotyping is very important in primary cervical cancer screening, as persistent infections with HR genotypes can progress to cervical cancer, especially in females aged 30 years or older. The Gambia is a small country in West Africa with a population of less than 2 million [21] . Females between the ages of 15 and 65 years represent 52 % of the population, and most are at risk of being diagnosed with cervical cancer. The quadrivalent vaccine has been introduced in the urban region of The Gambia and this is the first report of HPV genotype distribution where most cervical cancer cases are reported.
Overall HPV prevalence was found to be 12.1 %, which is slightly lower than the 13 % prevalence reported for rural Gambia, 18 % in nearby Dakar, Senegal and 40.8 % in Egypt [3, 22, 23] . Of the 28 HPV-positive samples in this study, 12 (42.9 %) were HR-HPV genotypes and four (14.3 %) were pHR-HPV genotypes. This is somewhat higher than the HR-HPV prevalence reported for Dakar (17.4 %) and south-western Nigeria (19.6 %) [24, 25] , where both studies targeted women from 18 to 80 years of age. The differences in prevalence seen in these studies could be attributed to the different age groups targeted or, perhaps more importantly, could be due to variability in HPV genotype in different geographical locations. The higher HR-HPV prevalence seen in this study could also be a reflection of selection bias, since cervical samples were collected from individuals who chose to attend a sexual health clinic.
HPV 52 was the most common high-risk genotype identified, accounting for 31.3 % of the total HR/pHR HPV genotypes and 17.9 % of all genotypes. HPV 61 was the most frequent LR genotype identified, with an overall prevalence of 14.3 % and accounting for 33.3 % of all LR-HPV. In contrast to earlier work in rural Gambia, where HR-HPV 16 and LR-HPV 42 were the most common genotypes identified, this study showed that 89 % of HPV genotypes identified do not match those included in the quadrivalent vaccine [22] . Similarly, work carried out in an urban region of Senegal, the only country to neighbour The Gambia, also found that HPV 52 was the most common genotype [25] . The same observation was also seen in studies carried out in Kenya and Tanzania [2, 4, 26] . This augments the findings of Bruni et al. [27] [28] [29] [30] , indicating that HPV bivalent and quadrivalent vaccines may not be as effective in Africa as previously thought [31] [32] [33] . Considering the high burden of cervical cancer cases and the lower prevalence of HPV 16 and 18 in Africa, it could be that other HR-HPV genotypes may be responsible for the high burden of the disease. In addition, a study in Asia found that genotypes HR-HPV 52 and 58 (3.8 and 5.6 %, respectively) were associated with a number of cases of invasive cervical cancer and high squamous intra-epithelial lesions (HSIL) [34] . This finding further emphasizes the importance of determining the major circulating genotypes in a population before introduction of the HPV vaccine, and is an important step in effective HPV infection prevention strategies.
It was shown here that 10.7 % of participants were infected with HPV genotypes targeted by the quadrivalent vaccine and 35.7 % were positive for HPV genotypes included in the Gardasil 9 vaccine. This finding may have important public health implications, as the HPV quadrivalent vaccine may be of limited value in The Gambia if the circulating non-HPV 16 and 18 HR-genotypes are responsible for cervical cytological abnormalities and progression to cervical cancer.
DNA sequence analysis has shown that none of the HR/ pHR-HPV genotypes detected were homologous to isolates from Africa found in the GenBank database, but rather isolates from America, Asia and Europe. This indicates that it is possible that these HR/pHR-HPV genotypes were imported into The Gambia (Table 3) , highlighting a key difference from an earlier study in rural areas which found that many of the HR-HPV sequences were homologous to isolates from Africa [22] . Contributory factors may be linked to the fact that the urban area is a popular tourist destination, and therefore the lifestyle and sexual behaviour of the participants may be different. The isolate nominally allocated to HPV 35 may be a previously unrecognised type, as the partial L1 gene sequence differed by more than 10 % to the closest match, an HPV 35 genotype isolated in Ecuador (Table 3) . Further work is required to determine this.
Infection with HPV is common in young females; however, most of these infections are transient and regress within 12 months, with only a small percentage of women developing persistent infection [3, 35] . The high HPV prevalence peak seen in the 21-25-year age group follows population norms of sexual initiation, as 77.8 % of the participants had their sexual debut at the age of !18 years. A sharp decline in prevalence was observed in those greater than 40 years old, which is consistent with viral transience. A similar finding was also observed in Abuja, Nigeria [27] . Studies carried out in Africa and Asia have reported a biphasic or a flat-shaped HPV age-specific curve in older age groups [23, 36] . However, 41.7 % of the HR-HPV genotypes were found in the 26-30-year age group, which highlights the importance of early and regular HPV and cervical cancer screening. The study data also revealed that 93 % of participants had never undergone cervical cancer screening (Table 1) . This may be due to either lack of awareness about cervical cancer or accessibility to screening, or both. The Gambia Histopathology Laboratory is situated at EFSTH, Banjul and it is currently the only laboratory offering cytology in the country. In addition, there are no decentralized national cervical cancer screening programmes, thus making access to screening a significant problem.
Whilst HPV infection plays a vital role in cervical cancer development, other social and risk co-factors appear to contribute to the increased risk of disease progression. Bosch et al. [37] have also shown that females who had used hormone contraceptives for more than 5 years were at increased risk for developing cervical cancer, and the present work supports this assertion (Table 2) . However, association studies on HPV-positive females and long-term use of hormone contraceptives have failed to reach a consensus [38] . There is a potential association between HPV infection and prolonged use of hormone contraceptives in the development of cervical cancer, which needs to be addressed with a larger study population.
It was found that 98.9 % of participants whose partners have other sexual partners are at increased risk of being infected with HPV (AOR 3.5; P=0.30) but are not associated significantly with HPV infection (Table 2 ). Married participants who had had sexual intercourse in the previous 12 months without using condoms were found to be twice at risk of acquiring HPV infection when compared to unmarried participants (AOR 2.1, P>0.05). This interaction may be linked to polygamy, which is a common practice in The Gambia and Africa and has implications of increased frequency of sexual activity with more than one partner. In The Gambia, 39 % of females live in a polygamous union with one or more co-wives [39] , which increases the risk of acquiring and transmitting HPV. Furthermore, 91.7 % (22/24) of participants who were HPV-infected reported not using a condom during sexual intercourse in the preceding 12 months. The majority (80.6 %) of the respondents were married and were thus less likely than unmarried individuals to report using a condom during sexual intercourse. Another potential contributory factor is poor negotiating power with their partners on condom use during sexual intercourse, especially those in a polygamous relationship. However, using condoms in the preceding 12 months was found to be a protective factor against HPV infection (AOR 0.7, 95 % CI 0.2-35).
As also reported by Wall et al. [22] , this study found that the level of HPV infection was higher in the Fula ethnic group and that this group were significantly more susceptible to HPV infection (AOR 2.1; P=0.15) ( Table 2) . Similarly, Sighoko et al. [16] also noted an ethnicity variation in their study on cervical cancer in The Gambia. They found that the Fula ethnic group were more at risk of being diagnosed with cervical cancer compared to other ethnic groups. The differences seen in the prevalence of HPV infection among the different ethnic groups may be linked to possible genetic factors as previously reported [16, 22, 40] , or to FGM being a predisposing factor. FGM is a common cultural practice amongst certain ethnic groups in the Gambia, and more than 50 % of females have undergone FGM before the age of 5 years. However, 75 % of females aged 15-49 years had undergone FGM in The Gambia, with a slightly higher burden of 79 % seen in the rural area compared to 72 % in the urban area [39] . Data on FGM showed that all the Fula (9/9) females who were infected with HPV underwent FGM. In The Gambia, Wollof females are least likely to have had FGM and were found to be at reduced risk for HPV infection (AOR 0.5; P=0.35). In contrast to male circumcision, which is thought to be a protective factor against HPV infection in males and their female partners [41, 42] , this study showed that participants who had undergone FGM were twice as likely to be at risk of being diagnosed with HPV infection (AOR 2.1; P=0.12); however, FGM was not found to be associated significantly with HPV infection. Similarly, studies of Senegalese and Malian females also found FGM to be a risk factor for HPV infection [43, 44] . FGM is practised in many African countries, especially in north-eastern Africa where HPV and cervical cancer burdens are high. The association between FGM and HPV infection could be a result of genital tissue damage leading to chronic inflammation, rendering these females more susceptible to infection. Furthermore, since most females with FGM are susceptible to recurrent genital infection, this can result in an impaired immune response and therefore can lead to an inability to clear HPV infection.
It was shown that 50 % of participants infected with HPV were co-infected with Ureaplasma parvum/urealyticum. Others have also found a higher prevalence of Ureaplasma in females with high-grade squamous intra-epithelial lesions (HSIL) compared to those with normal cytology [45, 46] . Although Ureaplasma parvum/urealyticum infections are known to be sexually transmitted, they are often not diagnosed and treated. These microorganisms can cause chronic pelvic inflammatory disease and infertility if left untreated. In addition, Ureaplasma can damage the vaginal epithelium and cause cervical mucus degradation, thus potentially facilitating HPV progression to cervical cancer [47] . This work adds to the body of evidence that Ureaplasma infection is an important co-factor in HPV infection, and highlights the importance of testing for Ureaplasma parvum/urealyticum and providing appropriate treatment to HPV-infected females, especially those with abnormal cytological results.
In conclusion, there is an apparent difference between the major, circulating HR-HPV genotypes in urban and rural areas of The Gambia; however, both studies underscore the need for a multivalent vaccine that targets all major HR-HPV genotypes in the general population. Although the quadrivalent vaccine has been piloted in The Gambia, this study raises important public health issues in regard to HPV vaccination programmes in developing countries. The introduction of accessible HPV DNA testing and cytology screening would be beneficial to Gambian women in regard to cervical cancer prevention. In this work, participants were not screened for cervical cancer and future studies investigating HPV genotype distribution from cervical cancer specimens would be necessary for enhanced cervical cancer intervention strategies in The Gambia.
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